Projects

Senior Research Fellow
Ing. Milan Štefek, CSc.

International

Finished
  • Multi-target paradigm for innovative ligand identification in the drug discovery process
    Program: COST
    Duration: 4. 12. 2015 – 29. 10. 2020
  • Targeting Molecular Pathways of Glucolipotoxicity by a Novel Carboxymethylated Mercaptotriazinoindole Inhibitor of Aldo-Keto Reductase AKR1B1 In Diabetes, Inflammation and Age-related Neurodegeneration
    Program: Bilateral - other
    Duration: 1. 5. 2016 – 30. 4. 2019
  • COST BM1204 : An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease
    Program: COST
    Duration: 16. 7. 2012 – 13. 12. 2016
  • The characterization and functional effects of quercetin and its derivative CHNQ, a potent aldo keto reductase inhibitor, in colorectal cancer
    Program: Bilateral - other
    Duration: 1. 1. 2013 – 31. 12. 2015
  • COST CM1103 Structure-based drug design for diagnosis and treatment of neurological diseases
    Program: COST
    Duration: 28. 11. 2011 – 27. 11. 2015
  • The role of oxidative stress in apoptosis and dysfunction of pancreatic beta cells. The potential protective effect of novel pyridoindole antioxidants.
    Program: Bilateral - other
    Duration: 1. 4. 2009 – 30. 4. 2011
  • Computational design and preparation of 2,6-difluoro-4-pyrrol-1-yl-phenol derivatives as non-carboxylic acid aldose reductase inhibitors: Preclinical implications for pharmacological prevention of diabetic complication
    Program: Inter-governmental agreement
    Duration: 1. 1. 2005 – 30. 6. 2007
  • Antioxidants and aldose reductase blockade in prevention of late diabetic complications: study on new pyridoindole derivates
    Program: Inter-academic agreement
    Duration: 1. 1. 2004 – 31. 12. 2006

National

Current
  • Aldo-keto reductase inhibitors in the personalized therapy of several types of cancer
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
  • Development of multifunctional aldose reductase inhibitors based on triazinoindoles: Optimization of their biological activity, selectivity, bioavailability and antioxidant properties.
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
  • Multi-target approach to diverse molecular mechanisms of diabetic complications and other glucose toxicity related diseases
    Program: SRDA
    Duration: 1. 8. 2021 – 30. 6. 2025
Finished
  • Indole-1-acetic acid derivatives as aldose reductase inhibitors: structure – activity relationships
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Novel compounds in prevention and treatment of diseases caused by glucose toxicity
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Pharmacological intervention in glucose-toxicity in type 2 diabetes
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Multi-target paradigm for innovative ligand identification in the drug discovery process
    Program:
    Duration: 18. 4. 2016 – 17. 4. 2020
  • Aldo-keto reductases in chronic diseases – in silico modeling of significant enzymes and their complexes with indole derivatives
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2017
  • Indole-1-acetic acid derivatives as aldose reductase inhibitors: design, synthesis and biological activity
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2017
  • MVTS An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease
    Program: Other projects
    Duration: 1. 6. 2013 – 13. 12. 2016
  • CM1103 Structure-based drug design for diagnosis and treatment of neurological diseases
    Program: Other projects
    Duration: 1. 1. 2014 – 27. 11. 2015
  • Molecular modeling, synthesis and biological activity of substituted pyridoindoles as bifunctional agents in prevention of diabetic complications
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • IN SILICO, IN VITRO AND EX VIVO RESEARCH CONCERNING ANTI-INFECTIVE COMPOUNDS
    Program: SRDA
    Duration: 1. 1. 2011 – 31. 12. 2012
  • Could the diabetic cataract prevention be achieved by substituted pyridoindoles with their antioxidant and aldose reductase inhibitory potential? Study on in vitro cultivated eye lenses from rats
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Substituted pyridoindoles as antioxidants and aldose reductase inhibitors in multitarget treatment of diabetic complications: a preclinical study
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Evaluation of activity parameters of potential inhibitors of aldose reductase – a contribution to therapy of chronic diabetic complications
    Program: VEGA
    Duration: 1. 1. 2007 – 1. 12. 2009
  • Molecular mechanisms of new drugs influencing oxidative stress - important ethiopathogenetic factor of numerous diseases
    Program: SRDA
    Duration: 1. 9. 2006 – 31. 10. 2009
  • Carboxymethylated pyridoindoles as inhibitors of aldose reductase with antioxidant activity: preclinical implicators for pharmacological prevention of diabetic complications
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees